The AHA submitted comments June 26 to the House Ways and Means Subcommittee on Health for a hearing about improving value-based care. The AHA shared principles Congress should consider when designing alternative payment models to make participation more attractive for potential participants. Those principles include providing an adequate on-ramp and glidepath to transition to risk; including adequate risk adjustment; allowing voluntary participation and flexible design; balancing risk versus reward; and establishing guardrails to ensure participants don't compete against themselves when they achieve optimal cost savings and outcomes, among others. 

Additionally, the AHA was critical of the Centers for Medicare & Medicaid Services' newly proposed Transforming Episode Accountability Model — a mandatory bundled payment model — and suggested CMS make participation voluntary along with a host of other changes. The AHA also questioned design elements of CMS’ proposed Increasing Organ Transplant Access model, a mandatory payment model for kidney transplants. 

Related News Articles

Headline
The AHA Nov. 17 released Fast Facts: Is My Hospital Rural, featuring updated information on the important role rural hospitals play in their communities, the…
Headline
The Medicare Part A deductible for inpatient hospital services will increase by $60 in calendar year 2026 to $1,736, the Centers for Medicare & Medicaid…
Headline
Aetna’s new “level of severity inpatient payment” policy is now set to take effect Jan. 1, 2026, the company recently announced, along with providing…
Perspective
Public
Nov. 20 is National Rural Health Day. It’s an opportunity to recognize the many ways rural hospitals advance health in their communities, as well as raise…
Headline
The 43-day government shutdown ended last night when President Trump signed a funding bill into law, hours after the House passed the measure by a 222-209 vote…
Chairperson's File
Public
In last month’s Chair File, we talked about some of the key priorities the AHA has for the remainder of 2025, one of which is protecting the 340B Drug Pricing…